A61K 47/6829
Bacterial toxins
Official title: {Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A}
A61K47/6829 (Bacterial toxins) appears on 306 US grants and 431 published applications in this corpus.
Search patents in A61K- Granted patents
- 306
- Published applications
- 431
- Assignees
- 204
- Inventors
- 776
- Latest grant
- 25 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1982 | 1 | 0 |
| 1983 | 2 | 0 |
| 1984 | 1 | 0 |
| 1985 | 1 | 0 |
| 1986 | 0 | 0 |
| 1987 | 2 | 0 |
| 1988 | 0 | 0 |
| 1989 | 1 | 0 |
| 1990 | 1 | 0 |
| 1991 | 1 | 0 |
| 1992 | 1 | 0 |
| 1993 | 1 | 0 |
| 1994 | 3 | 0 |
| 1995 | 1 | 0 |
| 1996 | 1 | 0 |
| 1997 | 3 | 0 |
| 1998 | 7 | 0 |
| 1999 | 7 | 0 |
| 2000 | 7 | 0 |
| 2001 | 0 | 0 |
| 2002 | 4 | 5 |
| 2003 | 4 | 8 |
| 2004 | 3 | 6 |
| 2005 | 4 | 9 |
| 2006 | 4 | 14 |
| 2007 | 1 | 9 |
| 2008 | 7 | 11 |
| 2009 | 5 | 13 |
| 2010 | 7 | 7 |
| 2011 | 4 | 18 |
| 2012 | 6 | 9 |
| 2013 | 9 | 15 |
| 2014 | 12 | 26 |
| 2015 | 21 | 24 |
| 2016 | 24 | 30 |
| 2017 | 21 | 35 |
| 2018 | 25 | 25 |
| 2019 | 14 | 15 |
| 2020 | 19 | 33 |
| 2021 | 14 | 27 |
| 2022 | 11 | 21 |
| 2023 | 13 | 26 |
| 2024 | 12 | 25 |
| 2025 | 15 | 10 |
| 2026 | 6 | 10 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Antibodies against human and canine IL-13RA225 Aug 2026US 12,715,926 B2Wake Forest University Health Sciences
- Methods of treating an autoimmune disease with a human interleukin-3 (IL-3)-diphtheria toxin conjugate (DT-IL3)14 Jul 2026US 12,678,485 B2Stemline Therapeautics, Inc.
- Enediyne conjugates2 Jun 2026US 12,642,861 B2Synaffix B.V.
- Modified clostridial neurotoxins as vaccine and conjugate vaccine platforms28 Apr 2026US 12,611,464 B2The Medical College of Wisconsin, Inc.
- Therapeutic constructs for co-delivery of anti-cancer agent(s) and immune checkpoint inhibitor(s)24 Mar 2026US 12,582,658 B2Oregon Health & Science University
- Fap-targeted antibody-drug conjugates8 Oct 2026US 2026/0306653 A1Oncomatryx Biopharma, S.L.
- Enzymatic Removable Cell Penetration-Blocker (rCPB) Conjugated To A Tandem Peptide-Cytotoxin, Tandem Peptide-miRNA Chimeric Molecules Or Tandem Peptide-Antioncogenic miRNA For Targeted Cancer Cell Delivery, Off-Target Toxicity Minimization, Resistance Reduction, Gene Regulation, Anti-Tumor Immune Response Upregulation In The Tumor Microenvironment And Systemically, And Synergistic Enhancement Of Anti-Tumor Activity24 Sep 2026US 2026/0284217 A1
- Antigen binding molecule specifically binding to egfr and muc1, drug conjugate thereof, and medical use thereof13 Aug 2026US 2026/0232830 A1Jiangsu Hengrui Pharmaceuticals Co., Ltd.
- Anti-cd26 antibody and use thereof30 Jul 2026US 2026/0217852 A1Zonhon Biopharma Institute Inc.
- Modified clostridial neurotoxins as vaccines and conjugate vaccine platforms23 Jul 2026US 2026/0207764 A1The Medical College of Wisconsin, Inc.
Most cited
By later US patents
- Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells200US 6,653,104 B2Immunomedics, Inc. · 2003
- Antibody conjugates reactive with human carcinomas196US 5,869,045 ABristol-Myers Squibb Company · 1999
- Antitumor protein hybrid and process for the preparation thereof135US 4,379,145 AHidematsu Hirai · 1983
- Methods and compositions for generating bioactive assemblies of increased complexity and uses128US 7,534,866 B2IBC Pharmaceuticals, Inc. · 2009
- Methods and compositions for generating bioactive assemblies of increased complexity and uses112US 7,906,121 B2IBC Pharmaceuticals, Inc. · 2011